CD163 Tumor-Associated Macrophage Expression as a Predictor of Distant Metastasis in Invasive Breast Cancer: A Cross-Sectional Study CD163 and Metastasis
Abstract
Background: Breast cancer is the most common malignancy among women globally, with distant metastasis being the primary cause of mortality. The tumor microenvironment, particularly Tumor-Associated Macrophages (TAMs), plays a crucial role in cancer progression. This study aimed to evaluate the association between CD163 expression in TAMs and the presence of distant metastasis in patients with breast cancer.
Methods: A cross-sectional study was conducted on 71 patients with invasive breast cancer at Hasanuddin University Hospital in Makassar. CD163 expression in TAMs was analyzed using immunohistochemistry in formalin-fixed paraffin-embedded tissues. Clinical and pathological data were collected from the medical records. Statistical analyses were performed using the Chi-square test for categorical data and the Mann-Whitney U test for continuous data, with significance defined as p < 0.05. Associations are presented as odds ratios (ORs).
Results: Of the 71 patients, 59.2% showed a high level of CD163 expression in TAMs. A significant association was observed between high CD163 expression and advanced cancer stage (p < 0.001), high histopathological grading (p < 0.001), and distant metastasis status (p < 0.001). After adjusting for key confounders, high CD163 expression was associated with an 11.2-fold increase in the odds of distant metastasis (adjusted OR = 11.2; 95% CI: 3.5–35.8; p < 0.001).
Conclusion: High CD163 expression in TAMs is significantly associated with an increased risk of distant metastasis in breast cancer and correlates with more aggressive tumor characteristics. These findings indicate that CD163-positive TAMs represent a potential prognostic biomarker for risk stratification in patients with breast cancer.
Full text article
References
Barrios CH. Global challenges in breast cancer detection and treatment. Breast 2022;62(S1):S3–S6; doi: 10.1016/j.breast.2022.02.003. DOI: https://doi.org/10.1016/j.breast.2022.02.003
Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 2022;66(June):15–23; doi: 10.1016/j.breast.2022.08.010. DOI: https://doi.org/10.1016/j.breast.2022.08.010
Prihantono, Rusli R, Christeven R, et al. Cancer Incidence and Mortality in a Tertiary Hospital in Indonesia: An 18-Year Data Review. Ethiop J Health Sci 2023;33(3):515–522; doi: 10.4314/ejhs.v33i3.15. DOI: https://doi.org/10.4314/ejhs.v33i3.15
Hill BS, Sarnella A, D’Avino G, et al. Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer. Semin Cancer Biol 2020;60(August 2019):202–213; doi: 10.1016/j.semcancer.2019.07.028. DOI: https://doi.org/10.1016/j.semcancer.2019.07.028
Hourani T, Holden JA, Li W, et al. Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting. Front Oncol 2021;11(December):1–20; doi: 10.3389/fonc.2021.788365. DOI: https://doi.org/10.3389/fonc.2021.788365
Yu Z, Zou J, Xu F. Tumor-associated macrophages affect the treatment of lung cancer. Heliyon 2024;10(7):e29332; doi: 10.1016/j.heliyon.2024.e29332. DOI: https://doi.org/10.1016/j.heliyon.2024.e29332
Li M-Y, Ye W, Luo K-W. Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer. Pharmaceutics 2024;16(7):865; doi: 10.3390/pharmaceutics16070865. DOI: https://doi.org/10.3390/pharmaceutics16070865
Zhang S, Xiao X, Yi Y, et al. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Ther 2024;9(1):1–36; doi: 10.1038/s41392-024-01848-7. DOI: https://doi.org/10.1038/s41392-024-01848-7
Banerjee K, Kerzel T, Bekkhus T, et al. VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells. Cell Rep 2023;42(12):113507; doi: 10.1016/j.celrep.2023.113507. DOI: https://doi.org/10.1016/j.celrep.2023.113507
Qiu Y, Chen T, Hu R, et al. Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. Biomark Res 2021;9(1):72; doi: 10.1186/s40364-021-00327-3. DOI: https://doi.org/10.1186/s40364-021-00327-3
Allison E, Edirimanne S, Matthews J. Breast Cancer Survival Outcomes and Tumor- Associated Macrophage Markers : A Systematic Review and Meta-Analysis. Oncol Ther 2023;11(1):27–48; doi: 10.1007/s40487-022-00214-3. DOI: https://doi.org/10.1007/s40487-022-00214-3
Stavrou M, Constantinidou A. Tumor associated macrophages in breast cancer progression: implications and clinical relevance. Front Immunol 2024;15(July):1–7; doi: 10.3389/fimmu.2024.1441820. DOI: https://doi.org/10.3389/fimmu.2024.1441820
Mwafy SE, El-Guindy DM. Pathologic assessment of tumor-associated macrophages and their histologic localization in invasive breast carcinoma. J Egypt Natl Cancer Inst 2020;32(1); doi: 10.1186/s43046-020-0018-8. DOI: https://doi.org/10.1186/s43046-020-0018-8
Ni C, Yang L, Xu Q, et al. J o u r n a l o f C a n c e r CD68- and CD163-positive tumor infiltrating macrophages in non-metastatic breast cancer : a retrospective study and meta-analysis. 2019;10; doi: 10.7150/jca.33914. DOI: https://doi.org/10.7150/jca.33914
Liu T, Larionova I, Litviakov N, et al. Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy. OncoImmunology 2018;7(6); doi: 10.1080/2162402X.2018.1436922. DOI: https://doi.org/10.1080/2162402X.2018.1436922
Basak U, Sarkar T, Mukherjee S, et al. Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol 2023;14(November):1–22; doi: 10.3389/fimmu.2023.1295257. DOI: https://doi.org/10.3389/fimmu.2023.1295257
Bied M, Ho WW, Ginhoux F, et al. Roles of macrophages in tumor development: a spatiotemporal perspective. Cell Mol Immunol 2023;20(9):983–992; doi: 10.1038/s41423-023-01061-6. DOI: https://doi.org/10.1038/s41423-023-01061-6
Fang C, Cheung MY, Chan RC, et al. Prognostic Significance of CD163+ and/or CD206+ Tumor-Associated Macrophages Is Linked to Their Spatial Distribution and Tumor-Infiltrating Lymphocytes in Breast Cancer. Cancers 2024;16(11):2147; doi: 10.3390/cancers16112147. DOI: https://doi.org/10.3390/cancers16112147
Garvin S, Oda H, Arnesson L-G, et al. Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery. J Cancer Res Clin Oncol 2018;144(7):1253–1263; doi: 10.1007/s00432-018-2646-0. DOI: https://doi.org/10.1007/s00432-018-2646-0
Park JE, Dutta B, Tse SW, et al. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene 2019;38(26):5158–5173; doi: 10.1038/s41388-019-0782-x. DOI: https://doi.org/10.1038/s41388-019-0782-x
Ge Z, Ding S. The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy. Front Oncol 2020;10:590941; doi: 10.3389/fonc.2020.590941. DOI: https://doi.org/10.3389/fonc.2020.590941
Jeong H, Hwang I. Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer. 2019;22(1):38–51. DOI: https://doi.org/10.4048/jbc.2019.22.e5
Argentiero A, Andriano A, Caradonna IC, et al. Decoding the Intricate Landscape of Pancreatic Cancer: Insights into Tumor Biology, Microenvironment, and Therapeutic Interventions. Cancers 2024;16(13):2438; doi: 10.3390/cancers16132438. DOI: https://doi.org/10.3390/cancers16132438
Omilian AR, Cannioto R, Mendicino L, et al. CD163+ macrophages in the triple-negative breast tumor microenvironment are associated with improved survival in the Women’s Circle of Health Study and the Women’s Circle of Health Follow-Up Study. Breast Cancer Res 2024;26(1):1–12; doi: 10.1186/s13058-024-01831-8. DOI: https://doi.org/10.1186/s13058-024-01831-8
Authors
Copyright (c) 2026 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.